Trial Profile

Randomized multicentre pilot study of LCZ696 versus irbesartan in patients with chronic kidney disease: UK Heart And Renal Protection (HARP)-III

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Jul 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sacubitril/valsartan (Primary) ; Irbesartan
Indications Renal failure
Focus Therapeutic Use
Acronyms UK HARP-III
Sponsors Novartis

Most Recent Events

12 Jul 2018 Primary endpoint (measured GFR (mGFR) at 12 months ) has not been met, according to results published in the Circulation.
12 Jul 2018 Results published in the Circulation.
19 Sep 2016 Trial rationale, trial design and baseline data (n=414) published in the Nephrology Dialysis Transplantation.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com